CSRP1 Promotes Colon Adenocarcinoma Growth and Serves as an Independent Risk Biomarker for Worse Prognosis

Table 2

Kaplan-Meier overall survival analyses of enrolled COAD patients.

Variables	Cases (n = 167)	Survival months (mean ± S.D.)	5-year OS (%)	value
Age (years)
≤65	80	74.4 ± 3.4	77.9
>65	87	58.6 ± 4.1	50.7
Sex
Female	86	69.9 ± 3.9	66.2	0.408
Male	81	58.1 ± 3.3	60.7
Tumor location
Ascending colon	43	73.5 ± 4.6	72.7	0.190
Transverse colon	30	58.1 ± 6.4	52.7
Descending-sigmoid colon	94	65.5 ± 3.9	62.9
Tumor size (cm)
≤3.5	86	67.8 ± 4.0	65.7	0.579
>3.5	81	63.7 ± 4.0	61.4
T stage
T1	33	75.3 ± 5.9	70.0
T2	21	65.0 ± 6.5	63.6
T3	91	67.4 ± 3.5	67.7
T4	22	43.0 ± 7.6	35.2
Lymph node status
Negative	96	73.2 ± 3.3	66.9
Positive	71	56.0 ± 4.2	60.3
Chemotherapy
No or unknown	109	64.0 ± 3.5	56.6	0.088
Accepted	58	69.0 ± 3.9	78.1
CSRP1 protein level
Low	90	73.4 ± 3.5	71.6
High	77	58.7 ± 4.4	53.3